Back to Results

Boston Scientific Corp (BSX)

Boston Scientific Corp is a healthcare equipment company that develops, manufactures, and markets medical devices used in a range of interventional specialties worldwide. The company operates through two segments, MedSurg and Cardiovascular. Its MedSurg portfolio includes products for gastrointestinal care, urology, neurology, endoscopy, infection prevention, and related procedural technologies. In cardiovascular care, Boston Scientific provides devices used to diagnose and treat heart disease, including WATCHMAN FLX, implantable cardiac devices, monitoring systems, and products for rate and rhythm disorders as well as peripheral arterial and venous conditions. The company also supplies products used in cancer diagnosis and treatment. Boston Scientific was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. The company’s common stock is listed on the New York Stock Exchange under the symbol BSX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-BSX
$60.19
38.9% Upside
Undervalued
$61.76
42.5% Upside
Undervalued
Great
0.0%
October 28, 2026
17.2x
2.5x
3.0x
62.81 B
73.196 B
16.7%
99.7%
4.3
98.7%
Valuation • Fair Value

Boston Scientific Corp (NYSE-BSX) Fair Value by Valuation Model

Review the available estimates for Boston Scientific Corp (NYSE-BSX), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$60.19

Estimated upside of 38.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$64.34

Discounted cash flow valuation reference.

Ben Graham Formula Value

$28.13

Classic Ben Graham valuation formula reference.

EPV Fair Value

$28.80

Earnings power value estimate.

Comps Fair Value

$61.26

Comparable-company valuation reference.

Analyst Price Target

$61.76

Analysts imply upside of 42.5%.

How to read these valuation models

Use the 7 available valuation references for Boston Scientific Corp (NYSE-BSX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Boston Scientific Corp (NYSE-BSX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

20.996 B

Current operating scale indicator.

Revenue Forecast

21.316 B

Forward revenue estimate.

EBITDA

5.711 B

Current operating profitability reference.

EBITDA Forecast

6.546 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Boston Scientific Corp (NYSE-BSX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Boston Scientific Corp (NYSE-BSX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.50

No elevated caution signal from this screen.

Altman Z-Score

4.3

Relatively strong balance-sheet zone.

FCF / Net Income

98.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Boston Scientific Corp (NYSE-BSX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Boston Scientific Corp (NYSE-BSX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 28, 2026

Days to Earnings

40

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Boston Scientific Corp (NYSE-BSX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Boston Scientific Corp (NYSE-BSX) Stock Forecast & Technical Outlook

Review Boston Scientific Corp (NYSE-BSX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Boston Scientific Corp (NYSE-BSX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Boston Scientific Corp (NYSE-BSX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Boston Scientific Corp (NYSE-BSX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Boston Scientific Corp (NYSE-BSX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Boston Scientific Corp (NYSE-BSX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Boston Scientific Corp (NYSE-BSX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Boston Scientific Corp (NYSE-BSX) has a Strong Buy consensus, with 17 buy, 6 hold and 0 sell recommendations in the current data set.

Buy 17
Hold 6
Sell 0
FAQ • Fast Investor Answers

Boston Scientific Corp (NYSE-BSX) Stock FAQ

Data-supported answers about Boston Scientific Corp (NYSE-BSX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$60.19
Estimated upside 38.9%
Valuation Rating
Undervalued
Estimated upside of 38.9%
Analyst Target
$61.76
Implied upside 42.5%
Financial Health
Great
Current financial-health read

The current fair value estimate for Boston Scientific Corp (NYSE-BSX) is $60.19. This implies an estimated upside of 38.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 38.9% versus the current market price.

The available analyst price target for Boston Scientific Corp (NYSE-BSX) is $61.76. The analyst target implies estimated upside of 42.5%.

The current financial health read for Boston Scientific Corp (NYSE-BSX) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Boston Scientific Corp (NYSE-BSX) is October 28, 2026.

The latest available data indicates no current dividend yield for Boston Scientific Corp (NYSE-BSX).

The current P/E ratio listed for Boston Scientific Corp (NYSE-BSX) is 17.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Boston Scientific Corp is 62.81 B.

The current enterprise value listed for Boston Scientific Corp is 73.196 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Boston Scientific Corp is NYSE-BSX, and the stock is listed on NYSE.

Boston Scientific Corp (NYSE-BSX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Boston Scientific Corp is 16.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Boston Scientific Corp is 99.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B
COO NASDAQ Cooper Companies Inc Fair Value Undervalued Market Cap 10.516 B